Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 32 results found. Search for [ Lupin's revenue ]

Results 1 to 21 of 32
BusinessToday.In
April 30, 2020
Sensex, Nifty Live News Today: Companies set to announce their earnings are Reliance Industries, Tech Mahindra, Hindustan Unilever, Apollo Tricoat Tubes, Laurus Labs, Aditya Birla Money among others


BusinessToday.In
February 6, 2020
Share Market Update: BSE 30-share S&P Sensex ended 144 points higher at 41,313 and NSE 50-share index Nifty50 closed 44 points higher at 12,133.


PB Jayakumar
January 14, 2020
A couple of days ago, Lupin said that it had received two observations from the US health regulator following the inspection at its Nagpur manufacturing facility, one of its most modern plants


BusinessToday.In
New Delhi, November 12, 2019
The deal proceeds will be utilised to strengthen Lupin's balance sheet as well as provide growth capital to support organic and inorganic initiatives for our focus markets, says Lupin CEO Vinita Gupta


BusinessToday.In
New Delhi, November 6, 2019
Lupin Q2 results: Consolidated revenue from operations of the pharma major increased 10.3 per cent year-on-year (YoY) to Rs 4,359.7 crore in Q2FY20 as against Rs 3,951 crore in Q2FY19


BusinessToday.In
August 7, 2019
Cipla reported net income from operations for the three-month period under review at Rs 3,894.46 crore, as against Rs 3,845.84 crore during the year-ago period


BusinessToday.In
New Delhi, August 7, 2019
HCL Tech Q1 results: Consolidated revenue from operations increased by 8.14 per cent to Rs 16,427 crore in Q1FY20 as compared to Rs 13,878 crore in Q1FY19


PB Jayakumar
New Delhi, July 22, 2019
Zydus Cadila, India's fourth-largest drug company by revenue, is banking big on research of new drugs, even though others have bowed out. Zydus expects the new drug business to grow to Rs 3,500 crore in four-five years


BusinessToday.In
May 27, 2019
Share Market Live: Benchmark indices Sensex and Nifty ended on a positive note on Monday, driven by gains in banking stocks amid unabated foreign fund inflow, amid higher Asian markets.


PB Jayakumar
May 17, 2019
Despite the pressure of business in the US, pharma major Lupin Limited recorded a 5.2 per cent rise in revenues to Rs 16,369.4 crore in FY19


BusinessToday.In
New Delhi, May 15, 2019
Net profit after exceptional items was up 141.4 per cent at Rs 606.60 crore during the financial year ended March 31, 2019; sales for Q4 FY2019 were up 8.7 per cent at Rs 4,325.90 crore compared to Rs 3,978.50 crore in Q4 FY2018;


BusinessToday.In
April 24, 2019
Except auto, all other sectoral indices ended in green backed up by gains in bank, IT, energy, telecom and finance.


PB Jayakumar
New Delhi, November 26, 2018
Market changes and increased regulatory oversight in the US have hurt Lupin, but India's third-biggest drug maker is making efforts to come back.


P.B. Jayakumar
New Delhi, April 30, 2018
Drug companies are moving up the value chain, transforming into complex generic manufacturers with high end R&D facilities.


E. Kumar Sharma
New Delhi, January 10, 2018
By following the strategy of doing a few things well, V.C. Nannapaneni has helped Natco Pharma carve out a space for itself.


P.B. Jayakumar
New Delhi, December 11, 2017
Margin erosion and regulatory hurdles are hitting Indian pharma companies hard in their biggest market.


E. kumar sharma
New Delhi, December 11, 2017
Indian pharma companies are facing strong headwinds, but they are also exploring every new opportunity to ensure a quick recovery.


PB Jayakumar
New Delhi, October 11, 2017
The acquisition of Symbiomix and the 'Solosec' franchise will help Lupin expand its women's health specialty business. Lupin will pay $50 million upfront and the remaining $100 million over the next five years.


E Kumar Sharma
New Delhi, August 17, 2017
On August 3rd, the largest generic company operating in the US, Teva Pharmaceutical Industries (Teva in quickspeak) put out results that arguably jolted the world of global generic medicines.


P.B. Jayakumar
Delhi, May 1, 2017
An air of urgency has been visible at the Mumbai headquarters of the second-largest Indian pharmaceutical company by sales, Lupin Ltd, for the past three to four years.


PAGES 1 OF 2  12